Limits...
Osteoprotegerin in Cardiometabolic Disorders.

Pérez de Ciriza C, Lawrie A, Varo N - Int J Endocrinol (2015)

Bottom Line: The association of OPG with diabetic complications (neuropathy, nephropathy, or retinopathy) as well as with atherosclerosis, coronary artery calcification, morbidity, and mortality is pointed out.Moreover, OPG modulation by different treatments is also established.Besides, other associated diseases such as obesity, hypertension, and metabolic syndrome, which are known cardiovascular risk factors, are also considered.

View Article: PubMed Central - PubMed

Affiliation: Department of Clinical Chemistry, Clínica Universidad de Navarra, Avenida Pío XII 36, 31008 Pamplona, Spain.

ABSTRACT
Osteoprotegerin (OPG), a glycoprotein traditionally implicated in bone remodelling, has been recently related to cardiovascular disease (CVD). Human studies show a positive relationship between circulating OPG, vascular damage, and CVD, and as such OPG has emerged as a potential biomarker for CVD. This review focuses on the relationship between circulating OPG and different endocrine cardiometabolic alterations such as type 1 and 2 diabetes. The association of OPG with diabetic complications (neuropathy, nephropathy, or retinopathy) as well as with atherosclerosis, coronary artery calcification, morbidity, and mortality is pointed out. Moreover, OPG modulation by different treatments is also established. Besides, other associated diseases such as obesity, hypertension, and metabolic syndrome, which are known cardiovascular risk factors, are also considered.

No MeSH data available.


Related in: MedlinePlus

Summary of osteoprotegerin involvement in different endocrinological pathologies including diabetes, hypertension, obesity, and metabolic syndrome.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4442310&req=5

fig3: Summary of osteoprotegerin involvement in different endocrinological pathologies including diabetes, hypertension, obesity, and metabolic syndrome.

Mentions: Although OPG has traditionally been implicated in bone remodelling and it has been determined as a biomarker in osteoporosis, the aim of this review is to highlight the association of OPG to other pathologies such as diabetes types 1 and 2, obesity, metabolic syndrome, or hypertension (Figure 3).


Osteoprotegerin in Cardiometabolic Disorders.

Pérez de Ciriza C, Lawrie A, Varo N - Int J Endocrinol (2015)

Summary of osteoprotegerin involvement in different endocrinological pathologies including diabetes, hypertension, obesity, and metabolic syndrome.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4442310&req=5

fig3: Summary of osteoprotegerin involvement in different endocrinological pathologies including diabetes, hypertension, obesity, and metabolic syndrome.
Mentions: Although OPG has traditionally been implicated in bone remodelling and it has been determined as a biomarker in osteoporosis, the aim of this review is to highlight the association of OPG to other pathologies such as diabetes types 1 and 2, obesity, metabolic syndrome, or hypertension (Figure 3).

Bottom Line: The association of OPG with diabetic complications (neuropathy, nephropathy, or retinopathy) as well as with atherosclerosis, coronary artery calcification, morbidity, and mortality is pointed out.Moreover, OPG modulation by different treatments is also established.Besides, other associated diseases such as obesity, hypertension, and metabolic syndrome, which are known cardiovascular risk factors, are also considered.

View Article: PubMed Central - PubMed

Affiliation: Department of Clinical Chemistry, Clínica Universidad de Navarra, Avenida Pío XII 36, 31008 Pamplona, Spain.

ABSTRACT
Osteoprotegerin (OPG), a glycoprotein traditionally implicated in bone remodelling, has been recently related to cardiovascular disease (CVD). Human studies show a positive relationship between circulating OPG, vascular damage, and CVD, and as such OPG has emerged as a potential biomarker for CVD. This review focuses on the relationship between circulating OPG and different endocrine cardiometabolic alterations such as type 1 and 2 diabetes. The association of OPG with diabetic complications (neuropathy, nephropathy, or retinopathy) as well as with atherosclerosis, coronary artery calcification, morbidity, and mortality is pointed out. Moreover, OPG modulation by different treatments is also established. Besides, other associated diseases such as obesity, hypertension, and metabolic syndrome, which are known cardiovascular risk factors, are also considered.

No MeSH data available.


Related in: MedlinePlus